Ipamorelin: Growth Hormone Secretagogue Research Guide

<p>Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively agonizes the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. First synthesized by Novo Nordisk in the 1990s, ipamorelin was developed specifically to study pulsatile GH secretion with a high degree of receptor selectivity — a design goal that distinguished it from earlier growth hormone secretagogues.</p><h2>Molecular Profile</h2><p>Sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2 | Molecular Formula: C38H49N9O5 | MW: 711.85 g/mol | CAS: 170851-70-4</p><h2>GHSR-1a Mechanism and Selectivity</h2><p>Ipamorelin's primary mechanism of action is selective agonism of GHSR-1a, the primary receptor through which endogenous ghrelin stimulates GH release from pituitary somatotrophs. Ipamorelin was notable in preclinical research for its high selectivity — unlike earlier GHS compounds such as GHRP-2 and GHRP-6, ipamorelin demonstrated minimal stimulation of cortisol, prolactin, and ACTH release in animal models, making it a cleaner research tool for studying isolated GH secretion.</p><p>↗ Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. PubMed ID: 9849822</p><h2>Comparison with Related Secretagogues</h2><p>Ipamorelin is frequently studied alongside CJC-1295 (a GHRH analog) to examine the combined pulsatile + sustained GH release model. The complementary mechanism — ipamorelin at the GHSR-1a receptor, CJC-1295 at the GHRH receptor — creates a dual-pathway GH stimulation model used in research settings to examine growth hormone axis interactions.</p><h2>Research Applications</h2><ul><li>GHSR-1a receptor agonism and selectivity studies</li><li>Pulsatile GH secretion modeling in preclinical settings</li><li>Growth hormone axis research in animal models</li><li>Comparison studies vs. GHRP-2 and GHRP-6 for receptor selectivity</li><li>IGF-1 axis pathway research in preclinical models</li></ul><h2>Frequently Asked Questions</h2><p>Q: How is ipamorelin different from GHRP-2 and GHRP-6?</p><p>A: Ipamorelin demonstrates significantly higher receptor selectivity for GHSR-1a with minimal stimulation of cortisol, ACTH, or prolactin in preclinical models — making it a more selective GH research tool than earlier GHRP compounds.</p><p>Q: Why is ipamorelin often paired with CJC-1295 in research?</p><p>A: The combination targets two different nodes of the GH axis simultaneously: ipamorelin at GHSR-1a (ghrelin receptor) and CJC-1295 at the GHRH receptor, allowing researchers to study dual-pathway stimulation models.</p><p>Q: What purity is appropriate for ipamorelin research?</p><p>A: ≥99% HPLC purity with LC-MS identity confirmation. TX Research Peptides supplies ipamorelin at this standard.</p><p>Related: Ipamorelin Product Page → | CJC-1295/Ipamorelin Blend → | CJC-1295 No DAC Research Guide → | Sermorelin Research Guide →</p>